« Can we really compare and aggregate pro data between people and settings? Implications for multi-country clinical trials and HTA | Main | Quality and safety of human blood and blood products if the UK leaves the EU without a deal »

11/04/2019

Logo Kings Fund
If you prefer to receive this content via email, you can sign up to our twice-weekly bulletin here: https://www.kingsfund.org.uk/emails